Abstract
In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Current Medicinal Chemistry
Title: Arylpiperazines with Affinity Toward a1-Adrenergic Receptors
Volume: 9 Issue: 13
Author(s): F. Manetti, F. Corelli, G. Strappaghetti and M. Botta
Affiliation:
Keywords: arylpiperazine, 1-adrenergic receptor, alpha1-ar, pyridazinone derivative
Abstract: In the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent one of the most studied classes of molecules with affinity at α1-AR. In fact, a large amount of work has been done and reported, describing synthetic procedures, biological evaluation at both α1-AR and the corresponding subtypes, and structure-activity relationships (SARs). In this paper, a review based on a literature survey aimed at focusing on the structural properties that a compound should possess to show affinity toward α1-AR is presented. Moreover, the identification and optimization of the structural features of a hit compound derived from a pharmacophore-based database search, leading to a new class of arylpiperazinylalkyl pyridazinone derivatives with α1-AR affinity is reported.
Export Options
About this article
Cite this article as:
Manetti F., Corelli F., Strappaghetti G. and Botta M., Arylpiperazines with Affinity Toward a1-Adrenergic Receptors, Current Medicinal Chemistry 2002; 9 (13) . https://dx.doi.org/10.2174/0929867023369961
DOI https://dx.doi.org/10.2174/0929867023369961 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis of Novel 3(N,N-dialkylamino)alkyl/phenyl Substituted Thieno [2,3-d]pyrimidinones as H1-Anti-Histaminic and Antimicrobial Agents
Current Bioactive Compounds Editorial [Herbal Remedies in Pulmonary Medicine: A Word of Caution]
Current Respiratory Medicine Reviews Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics Common Variant in VEGFA and Response to Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
Current Molecular Medicine Membrane Rafts in the Respiratory System
Current Respiratory Medicine Reviews Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Editorial (Hot Topics: New Insights in the Pathogenesis and Treatment of Diabetic Retinopathy)
Current Medicinal Chemistry Angiotensin II Roles in Human Vascular Tone Control
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Lipoxins, The Novel Mediators of Gastroprotection and Gastric Adaptation to Ulcerogenic action of Aspirin
Current Pharmaceutical Design Transdermal Delivery of Lercanidipine Hydrochloride: Effect of Chemical Enhancers and Ultrasound
Current Drug Delivery The Role of Antiplatelet Agents in the Management of Patients Receiving Intracardiac Closure Devices
Current Pharmaceutical Design Simultaneous Determination of Telmisartan and Pitavastatin Calcium in Intestinal Perfusate by HPLC: Application to Intestinal Absorption Interaction Study
Pharmaceutical Nanotechnology The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Therapeutic Approach of Histamine H3 Receptors in Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Prophylactic Neuroprotection
Current Drug Targets Pensions and Low Sodium Salt: A Qualitative Evaluation of a New Strategy for Managing Hypertension in Rural South Africa
Current Aging Science The Effectiveness of Interventions to Address Health Inequalities During Pregnancy: A Review of Relevant Literature
Current Women`s Health Reviews Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus
Current Cardiology Reviews Genetic Variations and Subclinical Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology